Asset Details
Do you wish to reserve the book?
Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE
Do you wish to request the book?
Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE
2017
Overview
ObjectivesDeregulated production of interleukin (IL)-17 and IL-21 contributes to the pathogenesis of autoimmune disorders such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Production of IL-17 and IL-21 can be regulated by ROCK2, one of the two Rho kinases. Increased ROCK activation was previously observed in an SLE cohort. Here, we evaluated ROCK activity in a new SLE cohort, and an RA cohort, and assessed the ability of distinct inhibitors of the ROCK pathway to suppress production of IL-17 and IL-21 by SLE T cells or human Th17 cells.MethodsROCK activity in peripheral blood mononuclear cells (PBMCs) from 29 patients with SLE, 31 patients with RA and 28 healthy controls was determined by ELISA. SLE T cells or in vitro-differentiated Th17 cells were treated with Y27632 (a pan-ROCK inhibitor), KD025 (a selective ROCK2 inhibitor) or simvastatin (which inhibits RhoA, a major ROCK activator). ROCK activity and IL-17 and IL-21 production were assessed. The transcriptional profile altered by ROCK inhibitors was evaluated by NanoString technology.ResultsROCK activity levels were significantly higher in patients with SLE and RA than healthy controls. Th17 cells exhibited high ROCK activity that was inhibited by Y27632, KD025 or simvastatin; each also decreased IL-17 and IL-21 production by purified SLE T cells or Th17 cells. Immune profiling revealed both overlapping and distinct effects of the different ROCK inhibitors.ConclusionsROCK activity is elevated in PBMCs from patients with SLE and RA. Production of IL-17 and IL-21 by SLE T cells or Th17 cells can furthermore be inhibited by targeting the RhoA-ROCK pathway via both non-selective and selective approaches.
Publisher
Elsevier Limited
Subject
/ Aged
/ Arthritis, Rheumatoid - blood
/ Arthritis, Rheumatoid - genetics
/ Arthritis, Rheumatoid - immunology
/ Disease
/ Female
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
/ Kinases
/ Lupus
/ Lupus Erythematosus, Systemic - blood
/ Lupus Erythematosus, Systemic - genetics
/ Lupus Erythematosus, Systemic - immunology
/ Male
/ Protein Kinase Inhibitors - pharmacology
/ rho-Associated Kinases - antagonists & inhibitors
/ rho-Associated Kinases - metabolism
/ rhoA GTP-Binding Protein - antagonists & inhibitors
/ rhoA GTP-Binding Protein - metabolism
/ Serology
/ Surgery
